A Randomized Phase III Trial Comparing 16 To 18 Weeks Of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), Or Anastrozole (1 mg) In Postmenopausal Women With Clinical Stage II And III Estrogen Receptor Positive Breast Cancer COHORT B.

Trial Profile

A Randomized Phase III Trial Comparing 16 To 18 Weeks Of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), Or Anastrozole (1 mg) In Postmenopausal Women With Clinical Stage II And III Estrogen Receptor Positive Breast Cancer COHORT B.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Anastrozole (Primary) ; Exemestane (Primary) ; Letrozole (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jan 2017 Primary endpoint (Anti-tumor effect in terms of pathologic CR (pCR) rate to neoadjuvant chemotherapy (Cohort B)) has not been met.
    • 03 Jan 2017 Results from the ACOSOG-Z1031B (n=236) and time to recurrence by PEPI status among all ACOSOG Z1031 patients published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top